Airsonett Air4 provides a clinical improvement in Quality of Life for asthma patients within 3 months of treatment
A re-analysis of time to onset (TTO) from a previously published study by Boyle et al, using the Airsonett Air4 Temperature-controlled Laminar Airflow technology (TLA), by Professor Leif Bjermer (Department of Respiratory and Allergology, University Hospital Lund, Sweden), concludes that Nocturnal treatment with TLA provided a statistically significant and clinically relevant improvement in total Quality of Life score (AQLQ) within 3 months in patients with poorly controlled asthma. Questions related to sleep quality may provide the first signal of response already within a month after commencing treatment.
“Allergen elimination is one of the cornerstones in asthma management. (Brazier et al, Pedroletti et al) The rapid response to treatment is important from a clinical perspective allowing firm conclusions already after a short test period. This is highly appreciated” says Leif Bjermer, Professor Department of Respiratory and Allergology, University Hospital Lund, Sweden.
“We had previous indications that the clinical effects of the TLA technology were evident within 3-6 months. Having this now documented at three months as well as one month for sleep is fantastic” says Anders Due-Boje, CEO Airsonett AB.
For the full article in Respiratory Medicine, please visit:
About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed,and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.
For more information:
Anders Due-Boje, CEO, Airsonett AB
Tel: +46 70 526 03 00
Airsonett Air4 is a drug-free, home-based treatment option for patients with persistent allergic asthma who remain poorly controlled despite treatment with conventional pharmacological therapy. Airsonett uses the unique and patented Temperature-controlled Laminar Airflow technology (TLA) to significantly reduce allergens and other airborne irritants from the patient’s breathing zone during the night. Airsonett Air4 is a CE marked class 1 medical device intended to be used for the alleviation of symptoms of allergy-induced diseases such as allergic asthma and atopic eczema. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health-economy studies. Airsonett Air4 holds a 510(k) cleared class II approval from FDA. Airsonett AB is a Swedish company. The main shareowners are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information, visit www.airsonett.eu
Please visit https://airsonett.eu/clinical-evidence/ for an overview of the clinical documentation of Airsonett Air4 and the TLA-technology.